Google
VBIO 株価分析 — Valion Bio Inc (Healthcare >> Biotechnology)
VBIO に関するよくある質問
VBIOのROE（自己資本利益率）は？
Valion Bio IncのROEは-35.56%です。
VBIOの配当利回りは？
Valion Bio Incの配当利回りは0.00%です。
VBIOの品質スコア（Quality Score）は？
当社のAIはVBIOの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
VBIOは今が買い時ですか？
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
VBIOはどのセクターに属しますか？
Valion Bio IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
VBIO AI Analysis Summary
Our AI summary for VBIO: Valion Bio Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -35.56%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.29
Price
-0.04
(-11.98%)
Day Change
|
|
|---|
VBIO, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.29 |
| PBV / Sector |
0.04 / 44,105.10
GREAT
|
| Earning Per Share | -1.54 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.31 M
GREAT
|
| Average 1W Daily Value |
0.33 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:51 |
| Symbol | VBIO |
| Name | VALION BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.15 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1.38 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1305 E. Houston Street, San Antonio, TX, United States, 78205
Phone: 888 276 6888
Website: https://valionbio.com
Employees: 52
Sector: Healthcare >> Biotechnology
Description: Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
